Phase 2/3 RINGSIDE Trial of AL102 Can Proceed in Desmoid Tumors
January 4th 2021
January 4, 2021 — The pivotal phase 2/3 RINGSIDE trial, which is evaluating the potent, selective oral gamma secretase inhibitor AL102, has been permitted to proceed and can potentially be used as a registrational study for adolescent and adult patients with desmoid tumors.